Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
← catalyst calendarSponsored by Boundless Bio, Inc. (industry) · BOLD — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
19actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic decision made following an assessment of preliminary PK data from the Part 1 portion of the trial showing a lack of dose proportional exposure and the increasing complexity and associated development costs in this landscape.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-28 | actual | When the study began enrolling |
| Primary completion | 2025-06-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-25 | actual | The whole study's end, after follow-up |
| First posted | 2024-03-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Intervention
- Drug: BBI-825 — also filed as ribonucleotide reductase inhibitor
Primary outcomes
what the primary-completion date above is the date OFFrequency and severity of treatment emergent adverse events (TEAEs) of BBI-825
measured Start of Cycle 1 until 30 days following last dose (each cycle is 28 days)
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of BBI-825
measured Start of Cycle 1 until 30 days following last dose (each cycle is 28 days)
Permalink · BOLD's whole pipeline · Catalyst calendar · Every registered study · What changed